Loading
Total declarations
Companies
▲ Purchases (315 ops.)
▼ Sales (97 ops.)
Latest filing published 14 Mar 2012 for Ocera Therapeutics, Inc., €2,300.
Filing timeline
BuySaleBaker Biotech Capital (GP), LLC
First 200 filings with a declared amount
Insider track record
Disclosed buys
315
Disclosed sells
97
Signal history
No signal scores available.
Closed purchases
Market purchases
315
Positive at T+90
57%
Median T+90
+19.1%
Based on 60 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +484.9%Entry US$2.05 · Close at T+365 US$11.99
- +368.6%Entry US$2.42 · Close at T+365 US$11.34
- +167.1%Entry US$3.47 · Close at T+365 US$9.27
- +148.7%Entry US$3.51 · Close at T+365 US$8.73
- +527.7%Entry US$1.30 · Close at T+365 US$8.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Baker Biotech Capital (GP), LLC: trading record in brief
Filings by Baker Biotech Capital (GP), LLC span 14 companies, the busiest being Genomic Health Inc, Incyte Corp and Seagen Inc. In total, 428 filings cover trades dated from 24 February 2006 to 14 March 2012.
Market trades split into 315 purchases (€83.1M) and 97 sales (€47.8M). Taken together, the purchases exceed the sales by €35.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 8 share grants. So far in 2012, the count stands at 48 purchases and no sales.
A typical purchase (the median) is worth €83k. For 60 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 57% of cases, with a median move of +19.1%. They describe history only and say nothing certain about the share price ahead.
Most recently, on 14 March 2012, the filings show an open-market purchase worth €57k in Ocera Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Baker Biotech Capital (GP), LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations405 total
1,601 shares@ US$1.8858Common StockSEC:0001144204-12-014964:0
Canonical exit: 10 Jun 2012 (T+90)
4,363 shares@ US$1.87Common StockSEC:0001144204-12-014964:1
Canonical exit: 10 Jun 2012 (T+90)
32,155 shares@ US$2.3396Common StockSEC:0001144204-12-014964:2
Canonical exit: 10 Jun 2012 (T+90)
56,187 shares@ US$2.55Common StockSEC:0001144204-12-014964:3
Canonical exit: 10 Jun 2012 (T+90)
15,599 shares@ US$2.9581Common StockSEC:0001144204-12-014964:4
Canonical exit: 11 Jun 2012 (T+90)
7,484 shares@ US$2.9891Common StockSEC:0001144204-12-014964:5
Canonical exit: 12 Jun 2012 (T+90)
4,592 shares@ US$3.0055Common StockSEC:0001144204-12-014964:6
Canonical exit: 12 Jun 2012 (T+90)
2,346 shares@ US$29.8792Common StockSEC:0001144204-12-014101:0
Canonical exit: 5 Jun 2012 (T+90)
2,162 shares@ US$30.3638Common StockSEC:0001144204-12-014101:1
Canonical exit: 6 Jun 2012 (T+90)
1,763 shares@ US$29.4704Common StockSEC:0001144204-12-013004:0
Canonical exit: 30 May 2012 (T+90)
10,972 shares@ US$29.5205Common StockSEC:0001144204-12-013004:1
Canonical exit: 31 May 2012 (T+90)
10,225 shares@ US$29.9561Common StockSEC:0001144204-12-013004:2
Canonical exit: 3 Jun 2012 (T+90)
8,372 shares@ US$30.0688Common StockSEC:0001144204-12-013004:3
Canonical exit: 3 Jun 2012 (T+90)
4,270 shares@ US$29.0306Common StockSEC:0001144204-12-012151:0
Canonical exit: 27 May 2012 (T+90)
5,934 shares@ US$29.1085Common StockSEC:0001144204-12-012151:1
Canonical exit: 28 May 2012 (T+90)
19,552 shares@ US$29.0581Common StockSEC:0001144204-12-012151:2
Canonical exit: 29 May 2012 (T+90)
5,217 shares@ US$27.9769Common StockSEC:0001144204-12-010670:0
Canonical exit: 21 May 2012 (T+90)
638 shares@ US$27.9811Common StockSEC:0001144204-12-010670:1
Canonical exit: 22 May 2012 (T+90)
7,477 shares@ US$28.1238Common StockSEC:0001144204-12-010670:2
Canonical exit: 23 May 2012 (T+90)
7,341 shares@ US$28.437Common StockSEC:0001144204-12-009724:0
Canonical exit: 14 May 2012 (T+90)
3,944 shares@ US$28.8772Common StockSEC:0001144204-12-009724:1
Canonical exit: 15 May 2012 (T+90)
41 shares@ US$28.9625Common StockSEC:0001144204-12-009724:2
Canonical exit: 16 May 2012 (T+90)
11,021 shares@ US$29.6106Common StockSEC:0001144204-12-009724:3
Canonical exit: 16 May 2012 (T+90)
10,838 shares@ US$29.8548Common StockSEC:0001144204-12-009724:4
Canonical exit: 16 May 2012 (T+90)
150,000 shares@ US$20.8536Common StockSEC:0001144204-12-009102:0
Canonical exit: 10 May 2012 (T+90)
25 of 405 declarations
